Payment overview · 2025
General Payments
$444.34
22 reported records · 13 companies
Healthcare provider profile · identity verified
Alexis A Woods, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PHOENIX, AZ · NPI 1043201486
Verified facts
What the public records show
CMS Open Payments records show Alexis A Woods, MD received $444.34 in general payments during 2025 across 22 reported records.
Novo Nordisk Inc accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.41 | 23.1% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.42 | 13.6% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $56.41 | 12.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.56 | 9.6% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $30.67 | 6.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.19 | 5.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.99 | 5.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.34 | 5.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.47 | 4.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.62 | 4.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $14.41 | 3.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.13 | 3.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.72 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $444.34 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.70 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $56.41 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.34 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.56 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $42.56 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $30.67 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.19 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 156 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
156 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 654 | 190 |
| Levothyroxine Sodium | Levothyroxine Sodium | 551 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 442 | 119 |
| Lisinopril | Lisinopril | 348 | 101 |
| Losartan Potassium | Losartan Potassium | 335 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 255 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 243 | 70 |
| Simvastatin | Simvastatin | 227 | 61 |
| Metformin Hcl | Metformin Hcl | 190 | 55 |
| Omeprazole | Omeprazole | 176 | 56 |
| Glipizide Er | Glipizide | 165 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 48 |
| Gabapentin | Gabapentin | 157 | 56 |
| Ozempic | Semaglutide | 156 | 36 |
| Metformin Hcl Er | Metformin Hcl | 153 | 47 |
| Alendronate Sodium | Alendronate Sodium | 146 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 41 |
| Trazodone Hcl | Trazodone Hcl | 121 | 39 |
| Allopurinol | Allopurinol | 116 | 32 |
| Furosemide | Furosemide | 116 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 29 |
| Sertraline Hcl | Sertraline Hcl | 109 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 30 |
| Buspirone Hcl | Buspirone Hcl | 92 | 25 |
| Montelukast Sodium | Montelukast Sodium | 89 | 29 |
| Synthroid | Levothyroxine Sodium | 80 | 24 |
| Atenolol | Atenolol | 79 | 22 |
| Eliquis | Apixaban | 78 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 20 |
| Potassium Chloride | Potassium Chloride | 73 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 18 |
| Alprazolam | Alprazolam | 64 | 27 |
| Carvedilol | Carvedilol | 62 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 18 |
| Glipizide | Glipizide | 61 | 18 |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 19 |
| Famotidine | Famotidine | 56 | 18 |
| Spironolactone | Spironolactone | 54 | 14 |
| Tramadol Hcl | Tramadol Hcl | 54 | 20 |
| Ezetimibe | Ezetimibe | 53 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 17 |
| Estradiol | Estradiol | 45 | 12 |
| Fenofibrate | Fenofibrate | 44 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 21 |
| Lovastatin | Lovastatin | 42 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 12 |
| Meloxicam | Meloxicam | 40 | 12 |
| Valacyclovir | Valacyclovir Hcl | 40 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 12 |
| Nifedipine Er | Nifedipine | 39 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 28 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Lorazepam | Lorazepam | 34 | 13 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 12 |
| Valsartan | Valsartan | 33 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 32 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | 15 |
| Bupropion Xl | Bupropion Hcl | 31 | 11 |
| Acyclovir | Acyclovir | 30 | 11 |
| Trulicity | Dulaglutide | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 25 |
| Clonidine Hcl | Clonidine Hcl | 26 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 22 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Nystatin | Nystatin | 20 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 15 |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 11 |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Mirabegron Er | Mirabegron | 13 | suppressed |
| Captopril | Captopril | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $444.34 · 22 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, EVENITY, INSPIRE, KISUNLA, LEQVIO, NURTEC ODT, OFEV, Ozempic, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Tymlos, Veozah, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error